Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
OpenAI Restricts Astra AI Over Cyberattack Risks 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.
